-
Intraoperative radiotherapy combined with spinal stabilization surgery—a novel treatment strategy for spinal metastases based on a first single-center experiences J Neurooncol. (IF 3.9) Pub Date : 2024-04-23 P. Krauss, C. L. Wolfert, B. Sommer, B. Stemmer, G. Stueben, K. H. Kahl, E. Shiban
-
Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy J Neurooncol. (IF 3.9) Pub Date : 2024-04-23 Ting Sun, Bin Liu, Lize Cai, Youxin Zhou, Wei Yang, Yanyan Li
-
Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease J Neurooncol. (IF 3.9) Pub Date : 2024-04-22 Anna Laura Knoblauch, B.-I. Blaß, C. Steiert, N. Neidert, A. Puzik, E. Neumann-Haefelin, A. Ganner, F. Kotsis, T. Schäfer, H.P.H. Neumann, S. Elsheikh, J. Beck, J.-H. Klingler
-
Impact of concurrent antibody–drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-04-22 Yutaro Koide, Naoya Nagai, Sou Adachi, Masayuki Ito, Mariko Kawamura, Makoto Ito, Fumitaka Ito, Yurika Shindo, Takahiro Aoyama, Hidetoshi Shimizu, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira
-
Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model J Neurooncol. (IF 3.9) Pub Date : 2024-04-19 Katharina Conrad, Ronja Löber-Handwerker, Mohammad Hazaymeh, Veit Rohde, Vesna Malinova
-
Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse J Neurooncol. (IF 3.9) Pub Date : 2024-04-19 Kevin J. Bielamowicz, Mary Beth Littrell, Gregory W. Albert, Lora S. Parker, Sateesh Jayappa, Kenneth Aldape, Murat Gokden
-
Neuroradiological features of patients with bilateral macronodular adrenocortical disease and meningiomas associated or not with genetic variants of ARMC5– a case series J Neurooncol. (IF 3.9) Pub Date : 2024-04-17 Arthur Araújo Massoud Salame, Helaine Laiz Silva Charchar, José Paulo de Oliveira Dourado, Berenice Mendonca, Guilherme Asmar Alencar, Leonardo José Tadeu de Araújo, Paula Ricci Arantes, Nicollas Nunes Rabelo, Eberval Gadelha Figueiredo, Maria Candida Barisson Villares Fragoso
-
Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches J Neurooncol. (IF 3.9) Pub Date : 2024-04-17 Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Sylvia Adams, Brandon Santhumayor, Ying Meng, Zane Schnurman, Bernadine R. Donahue, Kenneth Bernstein, Cordelia Orillac, Rishitha Bollam, Maryann J. Kwa, Marleen Meyers, Ruth Oratz, Yelena Novik, Joshua S. Silverman, David H. Harter, John G. Golfinos, Douglas Kondziolka
-
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines J Neurooncol. (IF 3.9) Pub Date : 2024-04-17 Daniela Kocher, Lei Cao, Romain Guiho, Melanie Langhammer, Yun-Lu Lai, Pauline Becker, Hiba Hamdi, Dennis Friedel, Florian Selt, David Vonhören, Julia Zaman, Gintvile Valinciute, Sonja Herter, Daniel Picard, Johanna Rettenmeier, Kendra K. Maass, Kristian W. Pajtler, Marc Remke, Andreas von Deimling, Stefan Pusch, Stefan M. Pfister, Ina Oehme, David T.W. Jones, Sebastian Halbach, Tilman Brummer, Juan
-
National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario J Neurooncol. (IF 3.9) Pub Date : 2024-04-17 Jay Desai, Sujay Rajkumar, Matthew J. Shepard, John Herbst, Stephen M. Karlovits, Shakir Hasan, Zachary D. Horne, Rodney E. Wegner
-
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM) J Neurooncol. (IF 3.9) Pub Date : 2024-04-17 Lucy Gately, C. Mesía, J. M. Sepúlveda, S. del Barco, E. Pineda, R. Gironés, J. Fuster, M. Dumas, S. Gill, L. M. Navarro, A. Herrero, A. Dowling, R. de las Peñas, M. A. Vaz, M. Alonso, Z. Lwin, R. Harrup, S. Peralta, A. Long, P. Perez-Segura, E. Ahern, C. O. Garate, M. Wong, R. Campbell, K. Cuff, R. Jennens, O. Gallego, C. Underhill, M. Martinez-Garcia, M. Covela, A. Cooper, S. Brown, M. Rosenthal
-
Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis J Neurooncol. (IF 3.9) Pub Date : 2024-04-15 Neslihan Nisa Gecici, Muhammet Enes Gurses, Brandon Kaye, Natasha L. Frontera Jimenez, Chandler Berke, Elif Gökalp, Victor M. Lu, Michael E. Ivan, Ricardo J. Komotar, Ashish H. Shah
-
Gamma knife radiosurgery for clival metastasis: case series and systematic review J Neurooncol. (IF 3.9) Pub Date : 2024-04-10 Sakibul Huq, Regan M. Shanahan, Samuel Adida, Othman Bin-Alamer, Hussam Abou-Al-Shaar, Ajay Niranjan, Constantinos G. Hadjipanayis, L. Dade Lunsford
-
Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapy J Neurooncol. (IF 3.9) Pub Date : 2024-04-10 Natsuko Kondo, Tadatoshi Kinouchi, Manabu Natsumeda, Juntaro Matsuzaki, Eishu Hirata, Yoshinori Sakurai, Masayasu Okada, Minoru Suzuki
-
Assessment of multimodal treatment options in recurrent and persistent acromegaly: a systematic review and meta-analysis J Neurooncol. (IF 3.9) Pub Date : 2024-04-08 Seyed Farzad Maroufi, Manijeh Assar, MirHojjat Khorasanizadeh, Fatemeh Mahdavi Sabet, Mohammadmahdi Sabahi, Rocco Dabecco, Badih Adada, Gabriel Zada, Hamid Borghei-Razavi
-
Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience J Neurooncol. (IF 3.9) Pub Date : 2024-04-03 Leyla Mirzayeva, Murat Uçar, Ahmet Memduh Kaymaz, Esra Temel
Purpose To investigate the effect of intraoperative magnetic resonance imaging (Io MRI) on overall and progression-free survival (OS and PFS), on the extent of resection (EOR) in patients with glioma, and impact of the radiological diagnosis on the decision to continue the surgery when a residual mass was detected on Io MRI. Methods The study comprised 153 glioma patients who received surgical treatment
-
Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment J Neurooncol. (IF 3.9) Pub Date : 2024-04-02
Abstract Purpose Glioblastoma (GB) is the most common primary malignant brain tumor with the highest incidence occurring in older adults with a median age at diagnosis of 64 years old. While treatment often improves survival it brings toxicities and adverse events (AE). Here we identify sex differences in treatment patterns and AE in individuals ≥ 66 years at diagnosis with GB. Methods Using the SEER-Medicare
-
Perioperative psychological distress in patients with intracranial tumors; a single center study J Neurooncol. (IF 3.9) Pub Date : 2024-04-02 Michael-Karl Fehrenbach, Florian Wilhelmy, Tim Wende, Erdem Güresir, Johannes Kasper
Purpose Distress Thermometer (DT) was adopted to evaluate distress in neuro-oncology on a scale from 1 to 10. DT values above 4 indicate major distress and should initiate psycho(onco)logical co-therapy. However, data about peri-operative distress is scarce. Hence, we evaluated peri-operative distress levels in a neurosurgical patient cohort with various intracranial tumors using the DT. Methods We
-
Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States J Neurooncol. (IF 3.9) Pub Date : 2024-04-02
Abstract Background How pediatric medulloblastoma patients fare in Lower Middle-Income Country (LMICs) in South America is not well understood. Correspondingly, the aim of this study was to summarize the pediatric neurosurgical experience of an institution in La Paz, and compare outcomes to that of a generalized High Income Country (HIC) United States (US) experience. Methods A retrospective review
-
Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China J Neurooncol. (IF 3.9) Pub Date : 2024-04-02
Abstract Background Glioblastoma (GBM) stands as the most aggressive and prevalent primary brain malignancy. Tumor Treating Fields (TTFields), an innovative therapy complementing chemotherapy for GBM treatment, which can significantly enhance overall survival, disease progression-free survival, and patient’s quality of life. However, there is a dearth of health economics evaluation on TTFields therapy
-
Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models J Neurooncol. (IF 3.9) Pub Date : 2024-04-02 Saeedeh Mahmoodifar, Dhiraj J. Pangal, Josh Neman, Gabriel Zada, Jeremy Mason, Bodour Salhia, Tehila Kaisman-Elbaz, Selcuk Peker, Yavuz Samanci, Andréanne Hamel, David Mathieu, Manjul Tripathi, Jason Sheehan, Stylianos Pikis, Georgios Mantziaris, Paul K. Newton
Objective Brain metastases (BM) are associated with poor prognosis and increased mortality rates, making them a significant clinical challenge. Studying BMs can aid in improving early detection and monitoring. Systematic comparisons of anatomical distributions of BM from different primary cancers, however, remain largely unavailable. Methods To test the hypothesis that anatomical BM distributions differ
-
Repurposing mebendazole against triple-negative breast cancer CNS metastasis J Neurooncol. (IF 3.9) Pub Date : 2024-04-02 Adrian J. Rodrigues, Sophia B. Chernikova, Yuelong Wang, Thy T. H. Trinh, David E. Solow-Cordero, Ludmila Alexandrova, Kerriann M. Casey, Elizabeth Alli, Abhishek Aggarwal, Tyler Quill, Ashley K. Koegel, Brian J. Feldman, James M. Ford, Melanie Hayden-Gephart
Purpose Triple-negative breast cancer (TNBC) often metastasizes to the central nervous system (CNS) and has the highest propensity among breast cancer subtypes to develop leptomeningeal disease (LMD). LMD is a spread of cancer into leptomeningeal space that speeds up the disease progression and severely aggravates the prognosis. LMD has limited treatment options. We sought to test whether the common
-
Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status J Neurooncol. (IF 3.9) Pub Date : 2024-04-01 Johanna Jost, Klaus Völker, Ralf Brandt, Walter Stummer, Steffi Urbschat, Ralf Ketter, Dorothee Wiewrodt, Rainer Wiewrodt
Purpose Maximal cardiopulmonary exercise testing (max. CPET) provides the most accurate measurement of cardiorespiratory fitness. However, glioblastoma (GBM) patients often undergo less intensive tests, e.g., 6-min walk test or self-rating scales. This study aims to demonstrate feasibility and safety of max. CPET in GBM patients, concurrently evaluating their physical fitness status. Methods Newly
-
Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma J Neurooncol. (IF 3.9) Pub Date : 2024-04-01 Ling Duan, Yongqi He, Wenhui Guo, Yanru Du, Shuo Yin, Shoubo Yang, Gehong Dong, Wenbin Li, Feng Chen
Purpose To develop and validate a pathomics signature for predicting the outcomes of Primary Central Nervous System Lymphoma (PCNSL). Methods In this study, 132 whole-slide images (WSIs) of 114 patients with PCNSL were enrolled. Quantitative features of hematoxylin and eosin (H&E) stained slides were extracted using CellProfiler. A pathomics signature was established and validated. Cox regression analysis
-
Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma J Neurooncol. (IF 3.9) Pub Date : 2024-04-01
Abstract Purpose The proximate localization of MTAP, which encodes methylthioadenosine phosphorylase, and CDKN2A/B on Chromosome 9q21 has allowed the loss of MTAP expression as a surrogate for homozygous deletion of CDKN2A/B. This study aimed to determine whether MTAP status correlates with clinical outcomes and 11C-methionine uptake in astrocytomas with IDH mutations. Methods We conducted immunohistochemistry
-
Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse J Neurooncol. (IF 3.9) Pub Date : 2024-03-29
Abstract Purpose There remains no standard of care for patients with recurrent and chemorefractory glioblastoma. Re-irradiation (reRT) provides an additional management option. However, published series predominantly focus on small reRT volumes utilizing stereotactic hypofractionated regimens. Concerns regarding toxicity have limited utilisation of reRT for larger recurrences, however this may be mitigated
-
A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project J Neurooncol. (IF 3.9) Pub Date : 2024-03-27 Pablo Flores-Paco, Alicia Vargas-Aliaga, María Geraldina Guevara, Ignacio Lopera, Lucía Rodríguez Ruiz, María López-Herrero, Juan Adrián Camús, Javier López-González, Elizabeth Inga-Saavedra, Marina Montero, Isidoro Barneto, Mª Auxiliadora Gómez-España, Estela Ruiz, Marta Ruza, Ana Armenta, Amalia Palacios, Juan R. De La Haba-Rodríguez, Enrique Aranda
-
A systematic review of extraneural meningioma metastasis: timing, evolution and outlook J Neurooncol. (IF 3.9) Pub Date : 2024-03-26 Gina Watanabe, Kurtis Young, Erin Rauber, Mohammad Faizan Khan, Reannon Suzuki, Robert Riestenberg, Giuseppe E. Umana, Paolo Palmisciano
-
Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy J Neurooncol. (IF 3.9) Pub Date : 2024-03-25
Abstract Background and purpose We report outcomes following spine stereotactic body radiotherapy (SBRT) in metastatic non-small cell lung cancer (NSCLC) and the significance of programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR) mutation and timing of immune check point inhibitors (ICI) on local failure (LF). Materials and methods 165 patients and 389 spinal segments
-
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers J Neurooncol. (IF 3.9) Pub Date : 2024-03-23 Christoph Straube, Stephanie E. Combs, Denise Bernhardt, Jens Gempt, Bernhard Meyer, Claus Zimmer, Friederike Schmidt-Graf, Peter Vajkoczy, Arne Grün, Felix Ehret, Daniel Zips, David Kaul
-
Palliative care for in-patient malignant glioma patients in Germany J Neurooncol. (IF 3.9) Pub Date : 2024-03-20 Larissa Fink, Birgitt van Oorschot, Christiane von Saß, Maxine Dibué, Marie-Therese Foster, Heidrun Golla, Ronald Goldbrunner, Christian Senft, Aaron Lawson McLean, Martin Hellmich, Nazife Dinc, Raymond Voltz, Heiner Melching, Christine Jungk, Marcel A. Kamp
-
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition J Neurooncol. (IF 3.9) Pub Date : 2024-03-19 Wietse Geens, Nathalie Vanlaer, Lynn Nijland, Sven Van Laere, Julia Katharina Schwarze, Michaël Bruneau, Bart Neyns, Anne Rogiers, Johnny Duerinck
-
The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database J Neurooncol. (IF 3.9) Pub Date : 2024-03-16
Abstract Purpose Aggressive resection in surgically-accessible glioblastoma (GBM) correlates with improved survival over less extensive resections. However, the clinical impact of performing a biopsy before definitive resection have not been previously evaluated. Methods We analyzed 17,334 GBM patients from the NCDB from 2010–2014. We categorized them into: “upfront resection” and “biopsy followed
-
Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study J Neurooncol. (IF 3.9) Pub Date : 2024-03-15 Vladimir N. Kasatkin, Elizaveta N. Romanova, Elena V. Glebova, Alena A. Deviaterikova, Vera V. Tolchennikova, Anastasia A. Sharapkova, Piruza A. Manukyan, Nadezhda M. Karpova, Roza A. Sarkisyan, Alexander F. Karelin
-
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-03-08 Vincenzo Di Nunno, Giuseppe Lombardi, Matteo Simonelli, Giuseppe Minniti, Angela Mastronuzzi, Valentina Di Ruscio, Martina Corrà, Marta Padovan, Marta Maccari, Mario Caccese, Giorgia Simonetti, Arianna Berlendis, Mariangela Farinotti, Bianca Pollo, Manila Antonelli, Antonio Di Muzio, Angelo Dipasquale, Sofia Asioli, Dario De Biase, Alicia Tosoni, Antonio Silvani, Enrico Franceschi
-
Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis J Neurooncol. (IF 3.9) Pub Date : 2024-03-08 Lucca B. Palavani, Guilherme Melo Silva, Pedro G. L. B. Borges, Márcio Yuri Ferreira, Marcelo Porto Sousa, Marianna G. H. S. J. Leite, Leonardo de Barros Oliveira, Sávio Batista, Raphael Bertani, Allan Dias Polverini, André Beer-Furlan, Wellingson Paiva
-
Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis J Neurooncol. (IF 3.9) Pub Date : 2024-03-07 Thomas Graillon, Betty Salgues, Tatiana Horowitz, Laetitia Padovani, Romain Appay, Emeline Tabouret, Eric Guedj, Olivier Chinot
-
Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma J Neurooncol. (IF 3.9) Pub Date : 2024-03-06 Kiyotaka Yokogami, Takashi Watanabe, Shinji Yamashita, Asako Mizuguchi, Hideo Takeshima
-
Impact of trametinib on the neuropsychological profile of NF1 patients J Neurooncol. (IF 3.9) Pub Date : 2024-03-05 Eve Lalancette, Édith Cantin, Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand, Dorsa Sadat Kiaei, Valérie Larouche, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Tara McKeown, Luis H. Ospina, Stéphanie Vairy, Vijay Ramaswamy, Hallie Coltin, Serge Sultan, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker
-
Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1 J Neurooncol. (IF 3.9) Pub Date : 2024-03-05
Abstract Purpose Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder which commonly causes neoplasms leading to disfigurement or dysfunction. Mitogen-activated protein kinase inhibitors (MEKi) are generally well-tolerated treatments which target neural tumor progression in patients with NF1. However, cutaneous adverse events (CAEs) are common and may hinder patients’ abilities to remain
-
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-05 Andrew B. Barbour, Barbara Blouw, Lynne P. Taylor, Jerome J. Graber, Tresa McGranahan, Molly Blau, Lia M. Halasz, Simon S. Lo, Yolanda D. Tseng, Vyshak Venur, Jonathan T. Yang
-
Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly J Neurooncol. (IF 3.9) Pub Date : 2024-03-05
Abstract Purpose Predicting resistance to first-generation Somatostatin Receptor Ligands (fg-SRL) in Acromegaly patients remains an ongong challenge. Tumor-associated immune components participate in various pathological processes, including drug-resistance. We aimed to identify the immune components involved in resistance of fg-SRL, and to investigate biomarkers that can be targeted to treat those
-
Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients J Neurooncol. (IF 3.9) Pub Date : 2024-03-04 Sachiv Chakravarti, Cathleen C. Kuo, Foad Kazemi, Ashley Kang, Calixto-Hope Lucas, Victoria Croog, David Kamson, Karisa C. Shreck, Matthias Holdhoff, Chetan Bettegowda, Debraj Mukherjee
-
Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas J Neurooncol. (IF 3.9) Pub Date : 2024-03-04 Mark A. Davison, Daniel T. Lilly, Arpan A. Patel, Ahmed Kashkoush, Xiaoying Chen, Wei Wei, Edward C. Benzel, Richard A. Prayson, Samuel Chao, Lilyana Angelov
-
Clinical characteristics and predictive factors of delayed diagnosis in patients with sellar germ cell tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-04
Abstract Purpose To investigate the clinical characteristics and predictive factors associated with delayed diagnosis in patients with sellar germ cell tumors (GCTs), aiming for early diagnosis. Methods A total of 345 patients with sellar GCTs were retrospectively collected. Patients were classified into a delayed diagnosis group (> 6 months from onset to diagnosis) and a non-delayed diagnosis group
-
Effect of sarcopenia and frailty on outcomes among patients with brain metastases J Neurooncol. (IF 3.9) Pub Date : 2024-03-02 Mervyn Jun Rui Lim, Zheting Zhang, Yilong Zheng, Ivan Wei Loon Khoo, Rhianne Caitlin Vaz Xin Ying, Sophie Jia Qian Koh, Ethanyn Lim, Pei Ing Ngam, Betsy Soon, Ying Liang Low, Li Feng Tan, Kejia Teo, Vincent Diong Weng Nga, Tseng Tsai Yeo
-
Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers J Neurooncol. (IF 3.9) Pub Date : 2024-03-02 Kanji Nakagawa, Koji Takano, Kazumi Nishino, Shuichi Ohe, Takahiro Nakayama, Hideyuki Arita
-
Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 Yasuhito Kegoya, Yoshihiro Otani, Yohei Inoue, Ryo Mizuta, Fumiyo Higaki, Kana Washio, Shinichiro Koizumi, Kazuhiko Kurozumi, Joji Ishida, Kentaro Fujii, Norio Yamamoto, Yoshihiro Tanaka, Isao Date
-
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 James L. Rogers, Thomas Wall, Alvina A. Acquaye-Mallory, Lisa Boris, Yeonju Kim, Kenneth Aldape, Martha M. Quezado, John A. Butman, James G. Smirniotopoulos, Huma Chaudhry, Christina I. Tsien, Prashant Chittiboina, Kareem Zaghloul, Orwa Aboud, Nicholas G. Avgeropoulos, Eric C. Burton, David M. Cachia, Karan S. Dixit, Jan Drappatz, Erin M. Dunbar, Peter Forsyth, Edina Komlodi-Pasztor, Jacob Mandel,
Purpose Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited
-
CPLX2 is a novel tumor suppressor and improves the prognosis in glioma J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 Yuanbing Chen, Jieling Ning, Long Shu, Lingzhi Wen, Bokang Yan, Zuli Wang, Junhong Hu, Xiaokun Zhou, Yongguang Tao, Xuewei Xia, Jun Huang
-
The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-02-29
Abstract Purpose Currently, there remains a scarcity of established preoperative tests to accurately predict the isocitrate dehydrogenase (IDH) mutation status in clinical scenarios, with limited research has explored the potential synergistic diagnostic performance among metabolite, perfusion, and diffusion parameters. To address this issue, we aimed to develop an imaging protocol that integrated
-
Non-navigated 2D intraoperative ultrasound: An unsophisticated surgical tool to achieve high standards of care in glioma surgery J Neurooncol. (IF 3.9) Pub Date : 2024-02-28 Santiago Cepeda, Sergio García-García, Ignacio Arrese, Rosario Sarabia
-
Diverse learners: learning disabilities and quality of life following mind–body and health education interventions for adults with neurofibromatosis J Neurooncol. (IF 3.9) Pub Date : 2024-02-27
Abstract Purpose Neurofibromatosis (NF) is associated with low quality-of-life (QoL). Learning disabilities are prevalent among those with NF, further worsening QoL and potentially impacting benefits from mind–body and educational interventions, yet research on this population is scarce. Here, we address this gap by comparing NF patients with and without learning disabilities on QoL at baseline and
-
Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center J Neurooncol. (IF 3.9) Pub Date : 2024-02-22 Melek Tugce Yilmaz, Alper Kahvecioglu, Gozde Yazici, Sepideh Mohammadipour, Neyran Kertmen, Gokcen Coban Cifci, Faruk Zorlu
-
Prognostic factors analysis of diffuse midline glioma J Neurooncol. (IF 3.9) Pub Date : 2024-02-21 Jing Jiang, Wen-bin Li, Shao-wen Xiao
-
Validation of a methylation-based signature for subventricular zone involvement in glioblastoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-20 Felix Ehret, Oliver Zühlke, Leonille Schweizer, Johannes Kahn, Christoph Csapo-Schmidt, Siyer Roohani, Daniel Zips, David Capper, Sebastian Adeberg, Amir Abdollahi, Maximilian Knoll, David Kaul
-
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R. Sepahdari, David Cachia, Brigitte C. Widemann, Derald E. Brackmann, Joni K. Doherty, Michel Kalamarides, Marco Giovannini
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Pushan Dasgupta, Alexander Ou, Heather Lin, Timothy Gregory, Kristin D. Alfaro-Munoz, Ying Yuan, Vahid Afshar-Khargan, Carlos Kamiya-Matsuoka, Justin F. Rousseau, Nazanin K. Majd
-
Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Thais Baccili Cury Megid, Zeynep Baskurt, Lucy X. Ma, Carly C. Barron, Abdul Farooq, Marie Phillipe Saltiel, Xin Wang, Yvonne Bach, Hiroko Ayoama, Raymond W. Jang, Eric Chen, Patrick Veit-Haibach, Ben Wang, Sangeetha Kalimuthu, James Cotton, Rebecca Wong, Aruz Mesci, Elena Elimova
-
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Samuel A. Bobholz, Alisha Hoefs, Jordyn Hamburger, Allison K. Lowman, Aleksandra Winiarz, Savannah R. Duenweg, Fitzgerald Kyereme, Jennifer Connelly, Dylan Coss, Max Krucoff, Anjishnu Banerjee, Peter S. LaViolette